Education
About Us
Working with TipRanks
Follow Us
Claritas Pharmaceuticals (CLAZF)
OTHER OTC:CLAZF
Total Valuation
Claritas Pharmaceuticals has a market cap or net worth of ―. The enterprise value is ―.
Market Cap―
Enterprise Value―
Share Statistics
Claritas Pharmaceuticals has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Claritas Pharmaceuticals’s return on equity (ROE) is 2.79 and return on invested capital (ROIC) is 482.39%.
Return on Equity (ROE)2.79
Return on Assets (ROA)0.40
Return on Invested Capital (ROIC)482.39%
Return on Capital Employed (ROCE)-0.99
Revenue Per Employee―
Profits Per Employee10.00T>
Employee Count―
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Claritas Pharmaceuticals is ―. Claritas Pharmaceuticals’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value<0.01
Price to FCF0.00
Price to Operating Cash Flow>-0.01
PEG Ratio―
Income Statement
In the last 12 months, Claritas Pharmaceuticals had revenue of 0.00 and earned 4.21M in profits. Earnings per share was 0.16.
Revenue0.00
Gross Profit0.00
Operating Income-3.28M
Pretax Income-674.00K
Net Income4.21M
EBITDA-2.79M
Earnings Per Share (EPS)0.16
Cash Flow
In the last 12 months, operating cash flow was -953.00K and capital expenditures 0.00, giving a free cash flow of -953.00K billion.
Operating Cash Flow-953.00K
Free Cash Flow-953.00K
Free Cash Flow per Share-10.00T>
Dividends & Yields
Claritas Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta―
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)100.00
Average Volume (3m)―
Important Dates
Claritas Pharmaceuticals upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Claritas Pharmaceuticals as a current ratio of 0.14, with Debt / Equity ratio of 61.38%
Current Ratio0.14
Quick Ratio0.14
Debt to Market Cap69.31
Net Debt to EBITDA-0.33
Interest Coverage Ratio-14.56
Taxes
In the past 12 months, Claritas Pharmaceuticals has paid -4.88M in taxes.
Income Tax-4.88M
Effective Tax Rate7.25
Enterprise Valuation
Claritas Pharmaceuticals EV to EBITDA ratio is -0.33, with an EV/FCF ratio of -3.02.
EV to Sales0.00
EV to EBITDA-0.33
EV to Free Cash Flow-3.02
EV to Operating Cash Flow-3.02
Balance Sheet
Claritas Pharmaceuticals has $2.00K in cash and marketable securities with $0.00 in debt, giving a net cash position of -$546.00K billion.
Cash & Marketable Securities$2.00K
Total Debt$0.00
Net Cash-$546.00K
Net Cash Per Share-$10.00T>
Tangible Book Value Per Share-$0.30
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Claritas Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―